Recent 8-K filings for LBRX

• June 10, 2026, 4:16 PM ET leadership materiality 0.55 neutral item 5.02item 9.01 ◈ executive_change

  LB Pharmaceuticals CMO Anna Eramo resigns; will advise through September 15, 2026

  Anna Eramo, M.D., resigns as CMO effective June 15, 2026; transitions to advisor role through Sept 15, 2026.

• June 9, 2026, 4:05 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×2

  LB Pharma shareholders elect three Class I directors, ratify auditor at annual meeting

  Class I directors elected: Robert A. Lenz (20,059,577 for), Rebecca Luse (18,530,680), Ran Nussbaum (18,748,511).

• May 12, 2026, 4:21 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases

  LB Pharma Q1 net loss $19.1M; cash $365.6M; Phase 3 schizophrenia trial launched

  Net loss of $19.1M in Q1 2026 vs $5.3M in Q1 2025; R&D expenses rose $11.2M to $14.6M.

• March 26, 2026, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases

  LB Pharmaceuticals reports Q4 net loss $11.5M; cash $295.2M; advances LB-102 into Phase 3

  Positive Phase 2 (NOVA-1) results for LB-102 in acute schizophrenia met primary endpoint; Phase 3 NOVA-2 initiated March 2026 with data expected H2 2027.

• March 16, 2026, 7:59 PM ET leadership materiality 0.30 neutral item 5.02

  Director Zachary Prensky to retire from LB Pharmaceuticals board at 2026 annual meeting

  Zachary Prensky notified board on March 13, 2026; will not stand for reelection at the 2026 annual meeting.

• March 10, 2026, 7:59 PM ET leadership materiality 0.50 positive item 5.02item 7.01item 9.01

  LB Pharmaceuticals appoints Dr. Robert Lenz to Board and promotes Gad Soffer to COO

  Robert Lenz, M.D., Ph.D., appointed to Board as Class I director; brings over 20 years of neuroscience R&D experience.

• February 5, 2026, 6:59 PM ET other material materiality 0.75 neutral item 1.01item 3.02item 7.01item 8.01item 9.01 ◈ Equity Issuances ×2◈ Material Agreements

  LB Pharmaceuticals raises $100M in private placement; Phase 2 MDD trial for LB-102 starts early 2027

  Gross proceeds ~$100M from sale of 3.31M shares and 1.42M pre-funded warrants at $21.17/share.

• November 13, 2025, 6:59 PM ET other material materiality 0.50 neutral item 1.01item 9.01

  LB Pharmaceuticals expands office lease at One Penn Plaza, adds 4,634 sq ft

  Amendment adds 4,634 rentable sq ft on 10th floor; lease expires March 31, 2032.

• November 12, 2025, 6:59 PM ET leadership materiality 0.60 neutral item 8.01item 9.01

  LB Pharmaceuticals appoints Kaya Pai Panandiker as Chief Commercial Officer

  Effective Nov 10, 2025; Panandiker previously CCO at Neumora Therapeutics.

• November 6, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  LB Pharmaceuticals Reports Q3 2025 Results and Provides Trial Updates

  Net loss narrowed to $3.6M in Q3 2025 from $14.2M in Q3 2024.

• September 12, 2025, 7:59 PM ET other materiality 0.35 neutral item 5.03item 9.01 ◈ Governance Changes ×2

  LB Pharmaceuticals adopts amended charter and bylaws upon IPO closing on Sept 12, 2025

  Filed amended and restated certificate of incorporation with Delaware Secretary of State.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.55 · Most common event leadership

2 positive 1 negative 8 neutral

source · LBRX on sec.gov